Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1536-1546

  Bae, Sungho ^a   Ma, Kyungwan ^a   Kim, Tae Hyung ^b   Lee, Eun Seong ^c   Oh, Kyung Taek ^d   Park, Eun Seok ^b   Lee, Kang Choon ^b   Youn, Yu Seok ^b  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Chung Ang University   (South Korea)

Author keywords

Albumin nanoparticles; Apoptosis; Doxorubicin; TRAIL; Tumor targeting

Indexed keywords

ALBUMIN NANOPARTICLES; APOPTOTIC ACTIVITY; CANCER CELL LINES; CANCER CELLS; CYTOTOXIC; CYTOTOXIC EFFECTS; DESOLVATION; DOXORUBICIN; HUMAN SERUM ALBUMINS; SURFACE-MODIFIED; TRAIL; TUMOR CELLS; TUMOR NECROSIS FACTORS; TUMOR TARGETING;

BODY FLUIDS; CARBOXYLATION; CELL CULTURE; CELL DEATH; CYTOTOXICITY; DISEASES; LIGANDS; MAMMALS; NANOPARTICLES; PARTICLE SIZE ANALYSIS; THERMOGRAPHY (IMAGING);

TUMORS;

AMINE; DIMETHYLMALEIC ACID ANHYDRIDE; DOXORUBICIN; MALEIC ANHYDRIDE; NANOPARTICLE; SERUM ALBUMIN; TRANSFERRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMAGING SYSTEM; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THIOLATION; TRANSMISSION ELECTRON MICROSCOPY;

AMINES; ANIMALS; CELL DEATH; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NEOPLASMS; SERUM ALBUMIN; SURFACE PROPERTIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFERRIN;

MUS;

EID: 83355162399     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.050     Document Type: Article

References (43)

1. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
2. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
3. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
4. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003, 14:1122-1132.
5. Betancourt T., Brown B., Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond) 2007, 2:219-232.
6. Sutton D., Nasongkla N., Blanco E., Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007, 24:1029-1046.
7. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
8. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5:876-885.
9. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690.
10. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14:337-348.
11. Xiang H., Nguyen C.B., Kelley S.K., Dybdal N., Escandón E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004, 32:1230-1238.
12. Ivanov V.N., Bhoumik A., Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003, 22:3152-3161.
13. Schneider B., Munkel S., Krippner-Heidenreich A., Grunwald I., Wels W.S., Wajant H., et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis 2010, 1:1-10.
14. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
15. Lee E.S., Oh K.T., Kim D., Youn Y.S., Bae Y.H. Tumor pH-responsive flower-like micelles of poly(l-lactic acid)-b-poly(ethylene glycol)-b-poly(l-histidine). J Control Release 2007, 123:19-26.
16. Kim D., Gao Z.G., Lee E.S., Bae Y.H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm 2009, 6:1353-1362.
17. Chen Y., Bathula S.R., Li J., Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010, 285:22639-22650.
18. Kim T.H., Jiang H.H., Youn Y.S., Park C.W., Lim S.M., Jin C.H., et al. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution. J Pharm Sci 2011, 100:482-491.
19. Chae S.Y., Kim T.H., Park K., Jin C.H., Son S., Lee S., et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010, 9:1719-1729.
20. Youn Y.S., Shin M.J., Chae S.Y., Jin C.H., Kim T.H., Lee K.C. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol Lett 2007, 29:713-721.
21. Kim T.H., Jiang H.H., Park C.W., Youn Y.S., Lee S., Chen X., et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J Control Release 2011, 150:63-69.
22. Dreis S., Rothweiler F., Michaelis M., Cinatl J., Kreuter J., Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 2007, 341:207-214.
23. Weber C., Coester C., Kreuter J., Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 2000, 194:91-102.
24. Langer K., Balthasar S., Vogel V., Dinauer N., von Briesen H., Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003, 257:169-180.
25. Youn Y.S., Chae S.Y., Lee S., Jeon J.E., Shin H.G., Lee K.C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 2007, 73:84-93.
26. Tsunoda S., Ishikawa T., Yamamoto Y., Kamada H., Koizumi K., Matsui J., et al. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent. J Pharmacol Exp Ther 1999, 290:368-372.
27. Kaneda Y., Yamamoto Y., Tsunoda S., Kamada H., Tsutsumi Y., Hirano T., et al. Bioconjugation of tumor necrosis factor-α with the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency. Biochem Biophpys Res Commun 1997, 239:160-165.
28. Kim I., Kim T.H., Ma K., Lee E.S., Kim D., Oh K.T., et al. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug Chem 2010, 21:1513-1519.
29. Jiang H.H., Kim T.H., Lee S., Chen X., Youn Y.S., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 2011, 32:8529-8537.
30. Kim H., Park H., Lee J., Kim T.H., Lee E.S., Oh K.T., et al. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 2011, 32:1685-1693.
31. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
32. Irache J.M., Espuelas S. Albumin nanoparticles. Biological and pharmaceutical nanomaterials 2006, 185-208. Wiley-VCH, Germany. C. Kumar (Ed.).
33. Feinstein S.B., Cheirif J., Ten Cate F.J., Silverman P.R., Heidenreich P.A., Dick C., et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol 1990, 16:316-324.
34. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1044.
35. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007, 13:345-357.
36. Tiruppathi C., Naqvi T., Wu Y., Vogel S.M., Minshall R.D., Malik A.B. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci USA 2004, 101:7699-7704.
37. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
38. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001, 61:759-763.
39. Vyhlidal C., Li X., Safe S. Estrogen regulation of transferrin gene expression in MCF-7 human breast cancer cells. J Mol Endocrinol 2002, 29:305-317.
40. Habashy H.O., Powe D.G., Staka C.M., Rakha E.A., Ball G., Green A.R., et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 2010, 119:283-293.
41. El-Zawahry A., McKillop J., Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005, 5:1-9.
42. Tsai W.S., Yeow W.S., Chua A., Reddy R.M., Nguyen D.M., Schrump D.S., et al. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol Cancer Ther 2006, 5:2977-2990.
43. Gibson S.B., Oyer R., Spalding A.C., Anderson S.M., Johnson G.L. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000, 20:205-212.